Merck's blood vessel disorder drug succeeds in late-stage study
(Reuters) -Merck & Co said on Monday an experimental treatment it gained through its $11.5 billion deal for Acceleron Pharma met the main goal of a st...
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(Reuters) -Merck & Co said on Monday an experimental treatment it gained through its $11.5 billion deal for Acceleron Pharma met the main goal of a st...
By Colin Kellaher Merck & Co. on Monday said a Phase 3 study of its sotatercept drug candidate met the key goals as an add-on to stable background therapy for pulmonary arterial... | October 10, 2022
Horizon Therapeutics shares are down 50% from last year's highs. See why HZNP stock is one of the best investment opportunities in biotech today.
/PRNewswire/ -- The "Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022" report has been added to ResearchAndMarkets.com's offering. The...
Albireo Pharma, Inc. (NASDAQ:NASDAQ:ALBO) Q2 2022 Earnings Conference Call August 15, 2022, 16:30 ET Company Participants Hans Vitzthum - LifeSci Advisors Ron Cooper - CEO, President &...